GlassScriptPhysician profile
Kelly Tran
NPI 1851773188
$3,547.73
in general payments reported to CMS, 2019-2025
26 companies · $989 in 2025
The $989 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $456 · 2023: $931 · 2024: $1,048 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,905 · Consulting Fee: $63.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,904.96 |
| Consulting Fee | $63.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $663.21 | 2022-2025 | Cuvitru, Takhzyro, Eohilia |
| Astrazeneca Pharmaceuticals LP | $522.45 | 2022-2025 | Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $464.88 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $399.11 | 2022-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $246.09 | 2022-2024 | Hizentra, Haegarda |
| Novartis Pharmaceuticals Corporation | $180.68 | 2023-2025 | |
| Pfizer INC. | $167.55 | 2023-2024 | |
| Pharming Healthcare, INC. | $125.61 | 2022-2025 | Ruconest |
| Biohaven Pharmaceuticals, INC. | $123.75 | 2021 | |
| Octapharma USA, INC. | $93.33 | 2023-2024 | Cutaquig |
| Optinose US, INC. | $72.30 | 2023-2024 | |
| Adma Biomanufacturing LLC | $63.07 | 2024-2025 | |
| Biocryst US Sales Co., LLC | $52.46 | 2023-2025 | Orladeyo |
| Cycle Pharmaceuticals INC | $47.69 | 2025 | Sajazir |
| Aimmune Therapeutics, INC. | $45.28 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $44.52 | 2023-2025 | |
| Hikma Pharmaceuticals USA | $39.04 | 2024 | Ryaltris |
| Kaleo, INC. | $36.50 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $26.27 | 2025 | Neffy |
| Leo Pharma INC. | $25.50 | 2022 | |
| Lilly USA, LLC | $22.82 | 2024 | Ebglyss |
| Blueprint Medicines Corporation | $21.21 | 2025 | Ayvakit |
| Abbvie INC. | $19.16 | 2024 | |
| Merck Sharp & Dohme LLC | $17.85 | 2023 | |
| Grifols USA, LLC | $14.97 | 2022 | |
| Amgen INC. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.